Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07065773 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | PHASE2 | ACTIVE NOT_RECRUITING | 50 | — | — | May 5, 2025 | Sep 1, 2026 | Feb 4, 2026 | 5 | United States |
Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.
| Arm | Type | Description |
|---|---|---|
| Trichostatin A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Trichostatin A | DRUG | Topical Study Drug |
Inclusion Criteria: * Willingness to provide signed and dated written voluntary informed consent. * Adults with diagnosis of mild-to-severe DLSO/DSO affecting at least one great toenail. * Positive microscopic examination with KOH for dermatophyte hyphae. * Positive dermatophyte culture or mixed de...